In just two years, CHRISTUS Santa Rosa Health System has assembled a team of nearly 40 urologic oncologists and other specialists from across San Antonio that focuses on diagnosing, treating and preventing urologic cancers in south Texas, close to where patients live and work.
A multi-institution clinical trial involving researchers from UT Health San Antonio shows significantly lower recurrence of bladder cancer in patients who received the chemotherapy drug gemcitabine.
ThuLEP: Laser Treatment for Benign Prostatic Hyperplasia Offers New Standard of Care at University Health System
No matter the size of the gland, thulium laser enucleation of the prostate (ThuLEP) offers next-day resolution of benign prostatic hyperplasia (BPH) symptoms without the need for extended hospital stays or invasive surgery.
A new study released in March found that many men receiving prostate specific antigen (PSA) testing do so without a comprehensive shared decision-making process, contrary to current guidelines. The American Cancer Society study, appearing in Annals of Family Medicine, finds that in both 2010 and 2015 about six in 10 men who reported recent PSA testing said they had received at least one component of shared decision making with their healthcare providers. Meanwhile, only 1 in 10 with no PSA test reported receiving any component of shared decision making in both 2010 and 2015.
According to SEER Cancer Statistics Review 1975–2007 (Bethesda Maryland NCI 2010), the mortality rate from prostate cancer has dropped 39 percent in the age of the PSA screening.
The UT Medicine Urology physicians treat routine and complex conditions, from kidney stones to rare cancers.